表紙
市場調查報告書

肺動脈栓塞治療藥的全球市場 2019年∼2023年

Global Pulmonary Embolism Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 843040
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈栓塞治療藥的全球市場 2019年∼2023年 Global Pulmonary Embolism Therapeutics Market 2019-2023
出版日期: 2019年05月06日內容資訊: 英文 119 Pages
簡介

全球肺動脈栓塞治療藥市場,到目前為止非口服給藥型的抗凝固藥的肝素佔主導地位。口服給藥型的抗凝固藥,因為與傳統的非口服型醫藥品比較,幾乎無須監測病患,更加受歡迎。該市場,預計至2023年以9%的年複合成長率發展。

本報告提供全球肺動脈栓塞治療藥市場調查,市場概要,各給藥途徑、各地區的市場規模的變化與預測,市場成長要素及課題分析,市場趨勢,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 報告範圍

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模的預測

第5章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係
  • 市場情況

第6章 市場區隔:各給藥途徑

  • 市場區隔:各給藥途徑
  • 市場比較:各給藥途徑
  • 口服給藥
  • 非口服給藥
  • 市場機會:各給藥途徑

第7章 客戶形勢

第8章 地區形勢

  • 市場區隔:各地區
  • 市場比較:各地區
  • 北美
  • 歐洲
  • 亞洲
  • 市場牽引國
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 抗凝固解毒劑相關研究增加
  • 策略性聯盟
  • 有關再生療法的廣泛研究

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • 第一三共
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31245

About this market

The increasing awareness programs and campaigns are expected to trigger the pulmonary embolism therapeutics market growth during the forecast period. The increasing awareness campaigns will improve the awareness of the severity of blood clots, resulting in various patients undergoing diagnosis and treatment on time. Such growing popularity will eventually boost the market growth in the forthcoming years. Technavio's analysts have predicted that the pulmonary embolism therapeutics market will register a CAGR of 9% by 2023.

Market Overview

Increasing oral anticoagulants

Traditionally, the global pulmonary embolism therapeutics market was dominated by Heparin, an anticoagulant drug, which is administered through parenteral route. The market also had various other anticoagulant drugs that were approved; however, most of these drugs were administered through invasive routes. These drugs require no or very less patient monitoring unlike their predecessors from the parenteral route. This will further aid to the popularity of oral anticoagulants.

Preference for alternative therapies

The increasing popularity and the advances in alternative treatment methods are expected to pose a major challenge to the growth of the global pulmonary embolism therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the pulmonary embolism therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated and with the presence of a few market players. Several vendors in the market are also entering into strategic alliances to manufacture the drugs so that they could concentrate on their core competencies such as research. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Oral - Market size and forecast 2018-2023
  • Parenteral - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research on anticoagulant antidotes
  • Strategic alliances
  • Extensive research on regenerative therapies

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: RoA - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by RoA
  • Exhibit 19: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by RoA
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 48: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 49: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 50: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 51: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 52: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 53: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 54: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 55: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 56: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 57: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 58: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 59: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 60: Daiichi Sankyo Co. Ltd. - Vendor overview
  • Exhibit 61: Daiichi Sankyo Co. Ltd. - Business segments
  • Exhibit 62: Daiichi Sankyo Co. Ltd. - Organizational developments
  • Exhibit 63: Daiichi Sankyo Co. Ltd. - Geographic focus
  • Exhibit 64: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibit 65: Daiichi Sankyo Co. Ltd. - Key customers
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 73: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 74: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 75: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 76: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 77: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 78: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 79: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: Definition of market positioning of vendors
Back to Top